JON S SAXE Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JON S SAXE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JON S SAXE. JON S SAXE is Director in SCICLONE PHARMACEUTICALS INC ($SCLN) and Director in DURECT CORP ($DRRX) and in VistaGen Therapeutics, Inc. ($NA).
Latest Insider Trading Transactions of JON S SAXE
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DRRX, SCLN, VTGN
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 22 2021 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | M | 1.50 | 2,500 | 3,750 | 0 | ||
Mar 22 2021 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | M | 1.50 | 2,500 | 3,750 | 5,751 | 3.3 K to 5.8 K (+76.90 %) | |
Jan 04 2021 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.77 | 75,000 | 132,750 | 75,000 | ||
Jan 04 2021 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.77 | 75,000 | 132,750 | 75,000 | ||
Aug 24 2020 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | P | 0.69 | 30,000 | 20,700 | 50,000 | 20 K to 50 K (+150.00 %) | |
Jun 18 2020 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 2.33 | 55,000 | 128,150 | 55,000 | |
Jun 18 2020 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 2.33 | 55,000 | 128,150 | 55,000 | |
Apr 27 2020 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 0.40 | 75,000 | 29,850 | 75,000 | ||
Oct 22 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.41 | 75,000 | 105,750 | 75,000 | ||
Jun 20 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 0.58 | 55,000 | 31,999 | 55,000 | |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.56 | 2,900 | 1,623 | 150,000 | 147.1 K to 150 K (+1.97 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.56 | 74 | 41 | 147,100 | 147 K to 147.1 K (+0.05 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.56 | 626 | 350 | 147,026 | 146.4 K to 147 K (+0.43 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.56 | 3,449 | 1,922 | 146,400 | 143 K to 146.4 K (+2.41 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 1,400 | 775 | 142,951 | 141.6 K to 143 K (+0.99 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 400 | 221 | 141,551 | 141.2 K to 141.6 K (+0.28 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 1,800 | 993 | 141,151 | 139.4 K to 141.2 K (+1.29 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 300 | 165 | 139,351 | 139.1 K to 139.4 K (+0.22 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 500 | 275 | 139,051 | 138.6 K to 139.1 K (+0.36 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 1,400 | 764 | 138,551 | 137.2 K to 138.6 K (+1.02 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 300 | 164 | 137,151 | 136.9 K to 137.2 K (+0.22 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 1,751 | 955 | 136,851 | 135.1 K to 136.9 K (+1.30 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.55 | 100 | 55 | 135,100 | 135 K to 135.1 K (+0.07 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 7,898 | 4,304 | 135,000 | 127.1 K to 135 K (+6.21 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 100 | 54 | 127,102 | 127 K to 127.1 K (+0.08 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 300 | 163 | 127,002 | 126.7 K to 127 K (+0.24 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 15 | 8 | 126,702 | 126.7 K to 126.7 K (+0.01 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 200 | 109 | 126,687 | 126.5 K to 126.7 K (+0.16 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 1,200 | 653 | 126,487 | 125.3 K to 126.5 K (+0.96 %) |
Jun 11 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.54 | 287 | 156 | 125,287 | 125 K to 125.3 K (+0.23 %) |
May 28 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.63 | 4,600 | 2,899 | 125,000 | 120.4 K to 125 K (+3.82 %) |
May 28 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.63 | 21,335 | 13,443 | 120,400 | 99.1 K to 120.4 K (+21.54 %) |
May 28 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.63 | 4,065 | 2,561 | 99,065 | 95 K to 99.1 K (+4.28 %) |
May 28 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.00 | 50,000 | 50,000 | 50,000 | ||
May 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.71 | 2,200 | 1,558 | 95,000 | 92.8 K to 95 K (+2.37 %) |
May 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 6,500 | 4,581 | 92,800 | 86.3 K to 92.8 K (+7.53 %) |
May 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 900 | 634 | 86,300 | 85.4 K to 86.3 K (+1.05 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 800 | 563 | 85,400 | 84.6 K to 85.4 K (+0.95 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 2,085 | 1,465 | 84,600 | 82.5 K to 84.6 K (+2.53 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 37 | 26 | 82,515 | 82.5 K to 82.5 K (+0.04 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 3,900 | 2,737 | 82,478 | 78.6 K to 82.5 K (+4.96 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 1,798 | 1,260 | 78,578 | 76.8 K to 78.6 K (+2.34 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 1,600 | 1,121 | 76,780 | 75.2 K to 76.8 K (+2.13 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 4,826 | 3,382 | 75,180 | 70.4 K to 75.2 K (+6.86 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 400 | 280 | 70,354 | 70 K to 70.4 K (+0.57 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 864 | 605 | 69,954 | 69.1 K to 70 K (+1.25 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 1,584 | 1,109 | 69,090 | 67.5 K to 69.1 K (+2.35 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 1,391 | 974 | 67,506 | 66.1 K to 67.5 K (+2.10 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 595 | 416 | 66,115 | 65.5 K to 66.1 K (+0.91 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 300 | 209 | 65,520 | 65.2 K to 65.5 K (+0.46 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 4,900 | 3,407 | 65,220 | 60.3 K to 65.2 K (+8.12 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.70 | 1,232 | 856 | 60,320 | 59.1 K to 60.3 K (+2.09 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 1,000 | 694 | 59,088 | 58.1 K to 59.1 K (+1.72 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 400 | 278 | 58,088 | 57.7 K to 58.1 K (+0.69 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 895 | 621 | 57,688 | 56.8 K to 57.7 K (+1.58 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 779 | 538 | 56,793 | 56 K to 56.8 K (+1.39 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 569 | 393 | 56,014 | 55.4 K to 56 K (+1.03 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 489 | 338 | 55,445 | 55 K to 55.4 K (+0.89 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 1,195 | 825 | 54,956 | 53.8 K to 55 K (+2.22 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 3,100 | 2,138 | 53,761 | 50.7 K to 53.8 K (+6.12 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 200 | 138 | 50,661 | 50.5 K to 50.7 K (+0.40 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.69 | 699 | 479 | 50,461 | 49.8 K to 50.5 K (+1.40 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.68 | 900 | 613 | 49,762 | 48.9 K to 49.8 K (+1.84 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.68 | 287 | 196 | 48,862 | 48.6 K to 48.9 K (+0.59 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.68 | 2,995 | 2,037 | 48,575 | 45.6 K to 48.6 K (+6.57 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.68 | 380 | 258 | 45,580 | 45.2 K to 45.6 K (+0.84 %) |
May 14 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.68 | 200 | 136 | 45,200 | 45 K to 45.2 K (+0.44 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 45,000 | 44.9 K to 45 K (+0.22 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 300 | 245 | 44,900 | 44.6 K to 44.9 K (+0.67 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 163 | 44,600 | 44.4 K to 44.6 K (+0.45 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 163 | 44,400 | 44.2 K to 44.4 K (+0.45 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 600 | 490 | 44,200 | 43.6 K to 44.2 K (+1.38 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 43,600 | 43.5 K to 43.6 K (+0.23 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 43,500 | 43.4 K to 43.5 K (+0.23 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 163 | 43,400 | 43.2 K to 43.4 K (+0.46 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 800 | 653 | 43,200 | 42.4 K to 43.2 K (+1.89 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 42,400 | 42.3 K to 42.4 K (+0.24 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 42,300 | 42.2 K to 42.3 K (+0.24 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 900 | 735 | 42,200 | 41.3 K to 42.2 K (+2.18 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 600 | 490 | 41,300 | 40.7 K to 41.3 K (+1.47 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 300 | 245 | 40,700 | 40.4 K to 40.7 K (+0.74 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 600 | 491 | 40,400 | 39.8 K to 40.4 K (+1.51 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 164 | 39,800 | 39.6 K to 39.8 K (+0.51 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 625 | 512 | 39,600 | 39 K to 39.6 K (+1.60 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 600 | 492 | 38,975 | 38.4 K to 39 K (+1.56 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 164 | 38,375 | 38.2 K to 38.4 K (+0.52 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 38,175 | 38.1 K to 38.2 K (+0.26 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 400 | 328 | 38,075 | 37.7 K to 38.1 K (+1.06 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 300 | 246 | 37,675 | 37.4 K to 37.7 K (+0.80 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 3,441 | 2,821 | 37,375 | 33.9 K to 37.4 K (+10.14 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 4,600 | 3,772 | 33,934 | 29.3 K to 33.9 K (+15.68 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 748 | 614 | 29,334 | 28.6 K to 29.3 K (+2.62 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 164 | 28,586 | 28.4 K to 28.6 K (+0.70 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 28,386 | 28.3 K to 28.4 K (+0.35 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 1,800 | 1,478 | 28,286 | 26.5 K to 28.3 K (+6.80 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 164 | 26,486 | 26.3 K to 26.5 K (+0.76 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 300 | 246 | 26,286 | 26 K to 26.3 K (+1.15 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 1,200 | 986 | 25,986 | 24.8 K to 26 K (+4.84 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 400 | 329 | 24,786 | 24.4 K to 24.8 K (+1.64 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 24,386 | 24.3 K to 24.4 K (+0.41 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 24,286 | 24.2 K to 24.3 K (+0.41 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 24,186 | 24.1 K to 24.2 K (+0.42 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 386 | 318 | 24,086 | 23.7 K to 24.1 K (+1.63 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 2,400 | 1,975 | 23,700 | 21.3 K to 23.7 K (+11.27 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 21,300 | 21.2 K to 21.3 K (+0.47 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 100 | 82 | 21,200 | 21.1 K to 21.2 K (+0.47 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 500 | 412 | 21,100 | 20.6 K to 21.1 K (+2.43 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.82 | 200 | 165 | 20,600 | 20.4 K to 20.6 K (+0.98 %) |
Mar 15 2019 | DRRX | DURECT CORP | SAXE JON S | Director | Buy | P | 0.83 | 400 | 330 | 20,400 | 20 K to 20.4 K (+2.00 %) |
Mar 14 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | P | 1.27 | 7,920 | 10,086 | 20,000 | 12.1 K to 20 K (+65.56 %) | |
Mar 14 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | P | 1.26 | 12,080 | 15,201 | 12,080 | 0 to 12.1 K | |
Jan 30 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | M | 1.50 | 1,000 | 1,500 | 0 | ||
Jan 30 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | M | 1.50 | 375 | 563 | 0 | ||
Jan 30 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | M | 1.50 | 1,000 | 1,500 | 3,251 | 2.3 K to 3.3 K (+44.42 %) | |
Jan 30 2019 | VTGN | VistaGen Therapeut ... | SAXE JON S | Buy | M | 1.50 | 375 | 563 | 2,251 | 1.9 K to 2.3 K (+19.99 %) | |
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 35,000 | 52,500 | 35,000 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 1.96 | 35,000 | 68,600 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 25,000 | 37,500 | 25,000 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 3.80 | 25,000 | 95,000 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 25,000 | 37,500 | 25,000 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 3.49 | 25,000 | 87,250 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 2,500 | 3,750 | 2,500 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 10.00 | 2,500 | 25,000 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 7,500 | 11,250 | 7,500 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 10.00 | 7,500 | 75,000 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 1,000 | 1,500 | 1,000 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 10.00 | 1,000 | 10,000 | 0 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.50 | 375 | 563 | 375 | ||
Aug 31 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | D | 10.00 | 375 | 3,750 | 0 | ||
Aug 06 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.27 | 75,000 | 95,250 | 75,000 | ||
Jun 20 2018 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 2.10 | 55,000 | 115,500 | 55,000 | |
Feb 05 2018 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.16 | 100,000 | 116,000 | 100,000 | ||
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 10.90 | 30,000 | 327,000 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 9.15 | 30,000 | 274,500 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 5.10 | 30,000 | 153,000 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 5.13 | 30,000 | 153,900 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 6.78 | 30,000 | 203,400 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 6.04 | 30,000 | 181,200 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 3.01 | 30,000 | 90,300 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 2.23 | 30,000 | 66,900 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | D | 1.75 | 30,000 | 52,500 | 0 | |
Oct 16 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Sell | D | 11.18 | 135,000 | 1,509,300 | 0 | 135 K to 0 (-100.00 %) |
Sep 20 2017 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.56 | 50,000 | 78,000 | 50,000 | ||
Jun 21 2017 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 1.40 | 16,038 | 22,453 | 71,038 | |
Jun 21 2017 | DRRX | DURECT CORP | SAXE JON S | Director | Option Exercise | A | 1.40 | 55,000 | 77,000 | 55,000 | |
Jun 09 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | A | 10.90 | 30,000 | 327,000 | 30,000 | |
Apr 28 2017 | VTGN | VistaGen Therapeut ... | SAXE JON S | Option Exercise | A | 1.96 | 35,000 | 68,600 | 35,000 | ||
Feb 23 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | M | 2.61 | 12,700 | 33,147 | 0 | |
Feb 23 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Buy | M | 2.61 | 12,700 | 33,147 | 135,000 | 122.3 K to 135 K (+10.38 %) |
Feb 17 2017 | SCLN | SCICLONE PHARMACEU ... | SAXE JON S | Director | Option Exercise | M | 2.61 | 17,300 | 45,153 | 12,700 |